Nourianz Reduces Duration of ‘Off Periods’ in Parkinson’s Patients with and without Dyskinesia, Analysis Finds

Nourianz Reduces Duration of ‘Off Periods’ in Parkinson’s Patients with and without Dyskinesia, Analysis Finds
When used as an add-on treatment to carbidopa-levodopa, Nourianz (istradefylline) reduced the duration of “off periods” — when symptoms are not adequately controlled — and increased the duration of “on periods” in Parkinson’s disease patients with and without pre-existing dyskinesia, a pooled analysis of several clinical trials has found. The findings, “Impact of Baseline Dyskinesia on the Safety and Efficacy of Istradefylline, ... read more
Source: Parkinson’s News TodayPublished on 2020-05-29By Joana Carvalho, PhD